The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2021

  • Pages
    234

  • View Count
    433

Example Insights

Cell-Therapy-Consumables-Market-Context Cell Therapy Consumables Market-List-of-Players Cell Therapy Consumables Market-Distribution-by-Company-Size-and-HQ Cell Therapy Consumables Market-Brand-Positioning-Analysis
Cell Therapy Consumables Market-Company-Competitiveness-Analysis Cell Therapy Consumables Market-Partnerships-and-Collaborations Cell Therapy Consumables Market-Strategic-Partners Cell Therapy Consumables Market-Demand-Analysis
Cell Therapy Consumables Market-Conservative-Base-and-Optimistic-Scenarios Cell Therapy Consumables Market-Opportunity    

 

Overview

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.  

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable / raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Scope of the Report

The “Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031” report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
  • An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area), service strength (based on its experience and company size) and number of products offered.
  • A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
  • Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
  • An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
  • An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
  • An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players, across the world, engaged in offering consumables for cell therapies?
  • Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
  • Which are the most popular media components used for cell therapy consumables?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
  • What are the key challenges associated with cell therapy consumables?
  • What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to consumables market for cell therapies?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the cell therapy consumables market and its likely evolution in the short to mid-term and long-term.

Chapter 3 provides a general introduction to cell therapies. It further includes a detailed discussion on the development and manufacturing process of cell therapies, along with information on the role of raw materials in cell therapy manufacturing. Furthermore, it provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development.

Chapter 4 provides a detailed overview of the cell therapy consumables landscape. It includes information related to over 60 industry players that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, location of headquarters, location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).

Chapter 5 features an insightful company competitiveness analysis, highlighting prominent consumable service providers, taking into consideration service strength of a company (based on its experience and company size), product portfolio (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) and number of products.

Chapter 6 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.

Chapter 7 provides elaborate profiles of key service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the cell therapy consumable industry, during the period between 2016 and 2021.

Chapter 9 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.

Chapter 10 provides an informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of cell therapy consumables market till 2031. We have segmented the market on the basis of [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 12 features an elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.

Chapter 13 highlights the effects of the recent COVID-19 pandemic on the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy consumables market, based on the research and analysis described in the previous chapters. 

Chapter 15 is a collection of transcripts of interviews conducted with various stakeholders in the industry. 

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Context and Background
3.2. Chapter Overview
3.3. Introduction to Cell Therapies
3.3.1. Comparison of Cell Therapies and Other Biotechnology Products
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development
3.7. Type of Cell Therapy Consumable
3.8. Key Challenges Associated with Cell Therapy Consumables
3.9. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Therapy Kit Providers: List of Players
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Kits Preparation Facilities
4.2.5. Analysis by Accreditations Received
4.2.6. Analysis by Type of End-User
4.2.7. Analysis by Type of Cell Therapy
4.2.8. Analysis by Type of Function
4.2.9. Analysis by Scale of Operation
4.2.10. Analysis by Application Area
4.2.11. Analysis by Application Area and Geography (Regional Landscape)

4.3. Cell Therapy Media Providers: List of Players
4.3.1. Analysis by Year of Establishment 
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Location of Media Preparation Facilities
4.3.5. Analysis by Accreditations Received
4.3.6. Analysis by Type of End-User
4.3.7. Analysis by Type of Cell Therapy
4.3.8. Analysis by Media Components
4.3.9. Analysis by Type of Function
4.3.10. Analysis by Scale of Operation
4.3.11. Analysis by Application Area
4.3.12. Analysis by Application Area and Geography (Regional Landscape)

4.4. Cell Therapy Reagent Providers: List of Players
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Location of Reagent Preparation Facilities
4.4.5. Analysis by Accreditations Received
4.4.6. Analysis by Type of End-User
4.4.7. Analysis by Type of Cell Therapy
4.4.8. Analysis by Type of Function
4.4.9. Analysis by Scale of Operation
4.4.10. Analysis by Application Area
4.4.11. Analysis by Application Area and Geography (Regional Landscape)
4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Company Competitiveness: Kit Providers
5.5. Company Competitiveness: Media Providers
5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview 
6.2. Scope and Methodology
6.3. Bio-Techne
6.4. Miltenyi Biotec
6.5. Sartorius
6.6. STEMCELL Technologies
6.7. Thermo Fisher Scientific

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Miltenyi Biotec
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. STEMCELL Technologies
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. Bio-Techne
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Irvine Scientific
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. Thermo Fisher Scientific
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Sartorius
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. BD Biosciences
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. Lonza
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.3. Recent Developments and Future Outlook

7.10. CellGenix
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.3. Recent Developments and Future Outlook

7.11. Corning
7.11.1. Company Overview
7.11.2. Product Portfolio
7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES 
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Consumable
8.3.5. Analysis by Type of Partnership and Type of Consumable
8.3.6. Analysis by Type of Cell Therapy
8.3.7. Analysis by Type of Consumable and Type of Cell Therapy
8.3.8. Most Active Players: Analysis by Number of Partnerships 
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Agreements
8.3.9.2. Local and International Agreements

8.3.10. Cumulative Year-wise Trend of Merger / Acquisition
8.3.11. Analysis by Type of Acquisition
8.3.12. Analysis by Key Value Drivers
8.3.13. Analysis by Year of Acquisition and Key Value Drivers

8.4. Cell Therapy Consumables: Recent Expansions
8.4.1. Analysis by Year of Expansion
8.4.2. Analysis by Purpose of Expansion
8.4.3. Analysis by Year and Purpose of Expansion
8.4.4. Analysis by Type of Consumable
8.4.5. Analysis by Purpose of Expansion and Type of Consumable
8.4.6. Analysis by Area of Expansion
8.4.7. Analysis by Region 
8.4.7.1. Analysis by Location of Consumable Facility (Continent-wise)
8.4.7.2. Analysis by Location of Consumable Facility (Country-wise)
8.4.8. Analysis by Purpose of Expansion and Location of Headquarters

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS   
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions 
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers
9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers 
9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers 
9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers 

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Demand for Cell Therapy Consumables
10.4. Global Demand for Cell Therapy Consumables for Planar Processes
10.5. Global Demand for Cell Therapy Consumables for Suspension Processes
10.6. Analysis by Scale of Operation
10.7. Analysis by Region 

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Global Outsourced Cell Therapy Consumables Market, 2021-2031

11.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable
11.4.1. Outsourced Cell Therapy Consumables Market for Kits, 2021-2031
11.4.2. Outsourced Cell Therapy Consumables Market for Media, 2021-2031
11.4.3. Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031

11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy
11.5.1. Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031
11.5.2. Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031
11.5.3. Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031
11.5.4. Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031
11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation
11.6.1. Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031
11.6.2. Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031

11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User
11.7.1. Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031
11.7.2. Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031

11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography
11.8.1. Outsourced Cell Therapy Consumables Market in North America, 2021-2031
11.8.2. Outsourced Cell Therapy Consumables Market in Europe, 2021-2031
11.8.3. Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031
11.8.4. Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
12.1. Chapter Overview
12.2. Emerging Trends Related to Cell Culture Media
12.3. Automation of Cell Therapy Manufacturing Processes 
12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market
13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers
13.4. Current Opinions and Key Initiatives of Key Players
13.5. Recuperative Strategies for Developer Businesses
13.5.1. Strategies for Implementation in the Short / Mid Term
13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS
14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS
15.1. Chapter Overview
15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies
15.2.1. Cellular Engineering Technologies: Key Highlights
15.2.2. Interview Transcript
15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories
15.3.1. HiMedia Laboratories: Key Highlights
15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Recent Developments
Figure 2.3 Executive Summary: Demand Analysis
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Type of Cell Therapy Consumable
Figure 4.1 Cell Therapy Consumables: Distribution by Type of Consumable
Figure 4.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
Figure 4.3 Cell Therapy Kit Providers: Distribution by Company Size
Figure 4.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Figure 4.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
Figure 4.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
Figure 4.7 Cell Therapy Kit Providers: Distribution by Type of End-User
Figure 4.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
Figure 4.9 Cell Therapy Kits: Distribution by Type of Function
Figure 4.10 Cell Therapy Kits: Distribution by Scale of Operation
Figure 4.11 Cell Therapy Kits: Distribution by Application Area
Figure 4.12 Regional Landscape: Distribution of Kit Providers by Application Area and Geography
Figure 4.13 Cell Therapy Media Providers: Distribution by Year of Establishment
Figure 4.14 Cell Therapy Media Providers: Distribution by Company Size
Figure 4.15 Cell Therapy Media Providers: Distribution by Location of Headquarters
Figure 4.16 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
Figure 4.17 Cell Therapy Media Providers: Distribution by Accreditations Received
Figure 4.18 Cell Therapy Media Providers: Distribution by Type of End-User
Figure 4.19 Cell Therapy Media: Distribution by Type of Cell Therapy
Figure 4.20 Cell Therapy Media: Distribution by Media Components
Figure 4.21 Cell Therapy Media: Distribution by Type of Function
Figure 4.22 Cell Therapy Media: Distribution by Scale of Operation
Figure 4.23 Cell Therapy Media: Distribution by Application Area
Figure 4.24 Regional Landscape: Distribution of Media providers by Application Area and Geography
Figure 4.25 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Figure 4.26 Cell Therapy Reagent Providers: Distribution by Company Size
Figure 4.27 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Figure 4.28 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
Figure 4.29 Cell Therapy Reagent Providers: Distribution by Accreditations Received
Figure 4.30 Cell Therapy Reagent Providers: Distribution by Type of End-User
Figure 4.31 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Figure 4.32 Cell Therapy Reagents: Distribution by Type of Function
Figure 4.33 Cell Therapy Reagents: Distribution by Scale of Operation
Figure 4.34 Cell Therapy Reagents: Distribution by Application Area
Figure 4.35 Regional Landscape: Distribution of Reagent Providers by Application Area and Geography
Figure 4.36 Grid Representation: Distribution by Type of Consumable, Type of Cell Therapy and Application Area
Figure 5.1 Company Competitiveness: Cell Therapy Kit Providers
Figure 5.2 Company Competitiveness: Cell Therapy Media Providers
Figure 5.3 Company Competitiveness: Cell Therapy Reagent Providers
Figure 6.1 Brand Positioning Matrix: Bio-Techne
Figure 6.2 Brand Positioning Matrix: Miltenyi Biotec  
Figure 6.3 Brand Positioning Matrix: Sartorius 
Figure 6.4 Brand Positioning Matrix: STEMCELL Technologies
Figure 6.5 Brand Positioning Matrix: Thermo Fisher Scientific 
Figure 7.1 Miltenyi Biotec: Product Portfolio
Figure 7.2 STEMCELL Technologies: Product Portfolio
Figure 7.3 Bio-Techne: Product Portfolio
Figure 7.4 Irvine Scientific: Product Portfolio
Figure 7.5 Thermo Fisher Scientific: Product Portfolio
Figure 7.6 Sartorius: Product Portfolio
Figure 7.7 BD Biosciences: Product Portfolio
Figure 7.8 Lonza: Product Portfolio
Figure 7.9 CellGenix: Product Portfolio
Figure 7.10 Corning: Product Portfolio
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Consumable
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.10 Partnerships and Collaborations: Local and International Agreements
Figure 8.11 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Figure 8.12 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 8.13 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 8.14 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.15 Recent Expansions: Distribution by Year of Expansion
Figure 8.16 Recent Expansions: Distribution by Purpose of Expansion
Figure 8.17 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 8.18 Recent Expansions: Distribution by Type of Consumable
Figure 8.19 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
Figure 8.20 Recent Expansions: Distribution by Area of Expansion
Figure 8.21 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
Figure 8.22 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
Figure 8.23 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 10.1 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
Figure 10.2 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
Figure 10.3 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
Figure 10.4 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Figure 10.5 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Figure 10.6 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
Figure 10.7 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
Figure 11.1 Global Outsourced Cell Therapy Consumables Market, 2021-2031 (USD Million)
Figure 11.2 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable
Figure 11.3 Outsourced Cell Therapy Consumables Market for Kits, 2021-2031 (USD Million)
Figure 11.4 Outsourced Cell Therapy Consumables Market for Media, 2021-2031 (USD Million)
Figure 11.5 Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031 (USD Million)
Figure 11.6 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy
Figure 11.7 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031 (USD Million)
Figure 11.8 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031 (USD Million)
Figure 11.9 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031 (USD Million)
Figure 11.10 Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031 (USD Million)
Figure 11.11 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation
Figure 11.12 Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031 (USD Million)
Figure 11.13 Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031 (USD Million)
Figure 11.14 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User
Figure 11.15 Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031 (USD Million)
Figure 11.16 Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031 (USD Million)
Figure 11.17 Outsourced Cell Therapy Consumables Market: Distribution by Region
Figure 11.18 Outsourced Cell Therapy Consumables Market in North America, 2021-2031 (USD Million)
Figure 11.19 Outsourced Cell Therapy Consumables Market in Europe, 2021-2031 (USD Million)
Figure 11.20 Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031 (USD Million)
Figure 11.21 Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031 (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Overview
Figure 14.2 Concluding Remarks: Recent Developments
Figure 14.3 Concluding Remarks: Demand Analysis
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
Figure 14.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Cell Therapies: Applications
Table 3.2 Differences between Cell Therapy and Biotechnology Product
Table 3.3 Key Cell Therapy Manufacturing Steps
Table 3.4 Types of Media Used in Cell Therapy Manufacturing
Table 7.1 Miltenyi Biotec: Key Highlights
Table 7.2 Miltenyi Biotec: Product Portfolio
Table 7.3 STEMCELL Technologies: Key Highlights
Table 7.4 STEMCELL Technologies: Product Portfolio
Table 7.5 STEMCELL Technologies: Recent Developments and Future Outlook
Table 7.6 Bio-Techne: Key Highlights
Table 7.7 Bio-Techne: Product Portfolio
Table 7.8 Bio-Techne: Recent Developments and Future Outlook
Table 7.9 Irvine Scientific: Key Highlights
Table 7.10 Irvine Scientific: Product Portfolio
Table 7.11 Irvine Scientific: Recent Developments and Future Outlook
Table 7.12 Thermo Fisher Scientific: Key Highlights
Table 7.13 Thermo Fisher Scientific: Product Portfolio
Table 7.14 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.15 Sartorius: Key Highlights
Table 7.16 Sartorius: Product Portfolio
Table 7.17 Sartorius: Recent Developments and Future Outlook
Table 7.18 BD Biosciences: Key Highlights
Table 7.19 BD Biosciences: Product Portfolio
Table 7.20 Lonza: Key Highlights
Table 7.21 Lonza: Product Portfolio
Table 7.22 CellGenix: Key Highlights
Table 7.23 CellGenix: Product Portfolio
Table 7.24 CellGenix: Recent Developments and Future Outlook
Table 7.25 Corning: Key Highlights
Table 7.26 Corning: Product Portfolio
Table 8.1 Cell Therapy Consumables: List of Partnerships and Collaborations, 2016-2021
Table 8.2 Cell Therapy Consumables Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2021
Table 8.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2021
Table 8.4 Cell Therapy Consumables: List of Recent Expansions, 2016-2021
Table 9.1 Key Potential Strategic Partners for Cell Therapy Consumable Providers
Table 9.2 Likely Partners for Dendritic Cell Therapy Consumable Providers
Table 9.3 Likely Partners for NK Cell Therapy Consumable Providers
Table 9.4 Likely Partners for Stem Cell Therapy Consumable Providers
Table 9.5 Likely Partners for T-Cell Therapy Consumable Providers
Table 15.1 Cellular Engineering Technologies: Key Highlights
Table 15.2 HiMedia Laboratories: Key Highlights
Table 16.1 Cell Therapy Consumables: Distribution by Type of Consumable
Table 16.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
Table 16.3 Cell Therapy Kit Providers: Distribution by Company Size
Table 16.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Table 16.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
Table 16.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
Table 16.7 Cell Therapy Kit Providers: Distribution by Type of End-User
Table 16.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
Table 16.9 Cell Therapy Kits: Distribution by Type of Function
Table 16.10 Cell Therapy Kits: Distribution by Scale of Operation
Table 16.11 Cell Therapy Kits: Distribution by Application Area
Table 16.12 Cell Therapy Media Providers: Distribution by Year of Establishment
Table 16.13 Cell Therapy Media Providers: Distribution by Company Size
Table 16.14 Cell Therapy Media Providers: Distribution by Location of Headquarters
Table 16.15 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
Table 16.16 Cell Therapy Media Providers: Distribution by Accreditations Received
Table 16.17 Cell Therapy Media Providers: Distribution by Type of End-User
Table 16.18 Cell Therapy Media: Distribution by Type of Cell Therapy
Table 16.19 Cell Therapy Media: Distribution by Media Components
Table 16.20 Cell Therapy Media: Distribution by Type of Function
Table 16.21 Cell Therapy Media: Distribution by Scale of Operation
Table 16.22 Cell Therapy Media: Distribution by Application Area
Table 16.23 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Table 16.24 Cell Therapy Reagent Providers: Distribution by Company Size
Table 16.25 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Table 16.26 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
Table 16.27 Cell Therapy Reagent Providers: Distribution by Accreditations Received
Table 16.28 Cell Therapy Reagent Providers: Distribution by Type of End-User
Table 16.29 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Table 16.30 Cell Therapy Reagents: Distribution by Type of Function
Table 16.31 Cell Therapy Reagents: Distribution by Scale of Operation
Table 16.32 Cell Therapy Reagents: Distribution by Application Area
Table 16.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.36 Partnerships and Collaborations: Distribution by Type of Consumable
Table 16.37 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Table 16.38 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 16.39 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
Table 16.40 Most Active Players: Distribution by Number of Partnerships
Table 16.41 Partnerships and Collaborations: Local and International Agreements
Table 16.42 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Table 16.43 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 16.44 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 16.45 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 16.46 Recent Expansions: Distribution by Year of Expansion
Table 16.47 Recent Expansions: Distribution by Purpose of Expansion
Table 16.48 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 16.49 Recent Expansions: Distribution by Type of Consumable
Table 16.50 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
Table 16.51 Recent Expansions: Distribution by Area of Expansion
Table 16.52 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
Table 16.53 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
Table 16.54 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 16.55 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
Table 16.56 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
Table 16.57 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
Table 16.58 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Table 16.59 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Table 16.60 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
Table 16.61 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
Table 16.62 Global Outsourced Cell Therapy Consumables Market, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.63 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable, 2021 and 2030
Table 16.64 Outsourced Cell Therapy Consumables Market for Kits, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.65 Outsourced Cell Therapy Consumables Market for Media, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.66 Outsourced Cell Therapy Consumables Market for Reagents, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.67 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2021 and 2030
Table 16.68 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.69 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.70 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.71 Outsourced Cell Therapy Consumables Market for T- Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.72 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation, 2021 and 2030
Table 16.73 Outsourced Cell Therapy Consumables Market for Clinical Operations, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.74 Outsourced Cell Therapy Consumables Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.75 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User, 2021 and 2030
Table 16.76 Outsourced Cell Therapy Consumables Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.77 Outsourced Cell Therapy Consumables Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.78 Outsourced Cell Therapy Consumables Market: Distribution by Geography, 2021 and 2030
Table 16.79 Outsourced Cell Therapy Consumables Market in North America, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.80 Outsourced Cell Therapy Consumables Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.81 Outsourced Cell Therapy Consumables Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.82 Outsourced Cell Therapy Consumables Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. Accellta
  3. Acer Therapeutics
  4. Activartis Biotech
  5. Adaptimmune
  6. Adicet Bio
  7. Aduro Biotech
  8. Advent Bioservices
  9. AGC Biologics
  10. AgenTus Therapeutics
  11. Agilent Technologies
  12. Ajinomoto
  13. Akadeum Life Sciences
  14. Akron Biotech
  15. Allele Biotechnology and Pharmaceuticals
  16. Allife Medical Science and Technology
  17. Allogene Therapeutics
  18. Altor BioScience
  19. American CryoStem
  20. Amphera
  21. AMSBIO
  22. Anhui Kedgene Biotechnology
  23. ANI Pharmaceuticals
  24. apceth Biopharma
  25. Applied Biological Materials
  26. Arbele
  27. Arcline Investment Management
  28. Argos Therapeutics
  29. Aspire Health Science
  30. Astellas Pharma
  31. Asterias Biotherapeutics
  32. AstraZeneca
  33. Atara Biotherapeutics
  34. ATCC
  35. Athersys
  36. Atlantis Bioscience
  37. Atreca Therapeutics
  38. Aurora Biopharma
  39. Austrianova
  40. Autolus
  41. Avantor
  42. AVAX Technologies
  43. Axol Bioscience
  44. Basic Pharma
  45. Baxalta
  46. Baxter
  47. BD Biosciences
  48. Beijing Biohealthcare Biotechnology
  49. Beijing Doing Biomedical
  50. Beijing Immunochina Medical Science & Technology
  51. Beijing Sanwater Biological Technology
  52. Beijing Tricision Biotherapeutics 
  53. Beike Biotechnology
  54. Bellicum Pharmaceuticals
  55. Bio Elpida
  56. BioAtla
  57. BioCardia
  58. BioCare
  59. BioCentriq
  60. Bio-Connect
  61. Bioinova
  62. Biological Industries
  63. BioNTech
  64. BioRestorative Therapies
  65. Bio-Techne 
  66. bluebird bio
  67. Bone Therapeutics
  68. BrainStorm Cell Therapeutics
  69. Bristol-Myers Squibb
  70. C3i (Center of Excellence for Cellular Therapy)
  71. Caladrius Biosciences
  72. Capricor Therapeutics
  73. Captain T Cell
  74. CardioCell
  75. Carina Biotech
  76. CARsgen Therapeutics
  77. CAR-T (Shanghai) Biotechnology
  78. Cartherics
  79. Catalent Biologics
  80. Celgene
  81. Celixir
  82. Cell and Gene Therapy Catapult
  83. Cell Applications
  84. Cell Biologics
  85. Cell Biotech
  86. Cell Genesys
  87. Cell Therapies
  88. Cellaria
  89. Cell-Easy
  90. Cellectis
  91. Cellex Cell Professionals
  92. CellGenix
  93. Cellin Technologies
  94. Cellmed
  95. CellMP (A subsidiary of Emmecell)
  96. CELLnTEC Advanced Cell Systems
  97. CellPraxis
  98. CellProtect Nordic Pharmaceuticals
  99. CellProthera
  100. Cells Online
  101. Cellular Biomedicine Group
  102. Cellular Engineering Technologies
  103. Cellular Therapeutics
  104. Celonic
  105. Celprogen
  106. Celularity
  107. Celyad
  108. Censo Biotechnologies
  109. CHA Biolab
  110. Chengdu MedGenCell
  111. China Regenerative Medicine International
  112. CiMaas
  113. Clean Cells
  114. CO.DON
  115. Cogent Biosciences
  116. Cognate BioServices
  117. CoImmune
  118. Cook MyoSite
  119. Corestem
  120. Corning
  121. Creative Biolabs
  122. CRISPR Therapeutics
  123. Cyagen Biosciences
  124. Cytiva (A subsidiary of Danaher)
  125. Cytopeutics
  126. CytoSen Therapeutics (Acquired by Kiadis Pharma)
  127. Cytovac
  128. CyTuVax 
  129. Daiichi Sankyo
  130. DanDrit Biotech
  131. DCPrime
  132. Delta-Vir
  133. Dendreon
  134. DiscGenics
  135. ElevateBio
  136. Eli Lilly
  137. Endocyte
  138. Eureka Therapeutics
  139. Eutilex
  140. Ever Union Biotechnology 
  141. EXUMA Biotech
  142. Fate Therapeutics
  143. Ferrer Internacional
  144. Fibrocell Technologies
  145. Five Prime Therapeutics
  146. Formula Pharmaceuticals
  147. Fortress Biotech
  148. Fosun Kite Biotechnology
  149. Froceth
  150. Fujilfim Cellular Dynamics
  151. Fujifilm
  152. Gadeta
  153. Gamida Cell
  154. GC Cell (Formerly known as Green Cross Cell)
  155. Gemini Bio
  156. GenCure (A subsidiary of BioBridge Global)
  157. Genentech
  158. GenIbet Biopharmaceuticals
  159. Genzyme
  160. GigaGen 
  161. GlaxoSmithKline
  162. Global Cell Med
  163. Glycostem Therapeutics
  164. Gradalis
  165. Green Cross
  166. GRI Bio
  167. Guangzhou Trinomab Biotech
  168. Heat Biologics
  169. Hebei Senlang Biotechnology
  170. Hemostemix
  171. HengRui YuanZheng Bio-Technology
  172. HiMedia Laboratories
  173. Histocell
  174. Histogenics
  175. Holostem Terapie Avanzate
  176. Hunan Zhaotai Yongren Biotech
  177. IBA Lifesciences
  178. iCarTAB BioMed
  179. iCell Gene Therapeutics
  180. Immatics
  181. Immune Therapeutics
  182. Immunicum
  183. ImmunoCellular Therapeutics
  184. Immunocore
  185. Immunovative Therapies 
  186. Immutep
  187. IncoCell Tianjin (wholly-owned subsidiary of Boyalife Group)
  188. Incysus
  189. Innoprot
  190. Innovative Cellular Therapeutics
  191. Inovio Pharmaceuticals
  192. inRegen
  193. Intellia Therapeutics
  194. International Stem Cell Corporation
  195. InVitria
  196. Iovance Biotherapeutics
  197. Irvine Scientific (Acquired by FUJIFILM)
  198. ISTO Technologies
  199. Ivy Life Sciences
  200. iXCells Biotechnologies
  201. Janssen
  202. Japan Tissue Engineering
  203. Juno Therapeutics
  204. JW Biotechnology
  205. JW CreaGene
  206. Kadimastem
  207. Kangstem Biotech
  208. KBI Biopharma
  209. Kiadis Pharma
  210. Kiromic
  211. Kite Pharma
  212. Kuur Therapeutics
  213. LAgen Laboratories
  214. Laurus Bio (Formerly known as Richcore Lifesciences)
  215. Laurus Labs
  216. Legend Biotech
  217. Leucid Bio
  218. Lifecells
  219. Lineage Cell Therapeutics
  220. Lion TCR
  221. Living Pharma
  222. Longeveron
  223. Lonza
  224. Lumos Pharma
  225. Lykan Bioscience
  226. Marino Biotechnology
  227. MaxCyte
  228. Medeor Therapeutics
  229. Medigene
  230. MEDINET
  231. MEDIPOST
  232. MedVax Technologies
  233. Merck Serono
  234. Mesoblast
  235. Miltenyi Biotec
  236. Minaris Regenerative Medicine
  237. Minerva Biotechnologies
  238. Minovia Therapeutics
  239. MolecuVax
  240. Moraga Biotechnology
  241. Multimmune
  242. Mustang Bio 
  243. Nanjing KAEDI Biotech
  244. NantKwest
  245. Neopharm
  246. Neuralstem
  247. Neuromics
  248. Nikon CeLL innovation
  249. Nkarta
  250. Nohla Therapeutics
  251. Noile-Immune Biotech
  252. Northern Therapeutics
  253. Northwest Biotherapeutics
  254. Novadip Biosciences
  255. Novartis
  256. NovaRx (Acquired by Viropro)
  257. Novella Clinical
  258. Novex Innovations
  259. Nucleus Biologics
  260. Nuo Therapeutics
  261. OhioHealth
  262. OiDE BetaRevive
  263. Ology Bioservices
  264. Oncobiomed
  265. Opexa Therapeutics
  266. Orchard Therapeutics
  267. OrganaBio
  268. Osiris Therapeutics
  269. Oxford BioMedica
  270. PAN-Biotech
  271. PDC*line Pharma
  272. PELOBiotech
  273. PeproTech
  274. PersonGen BioTherapeutics
  275. Pfizer
  276. PharmaBio
  277. Pharmicell
  278. PhoenixSongs Biologicals
  279. Pinze Lifetechnology
  280. Pique Therapeutics
  281. Pluristem Therapeutics
  282. Plus Therapeutics
  283. Poseida Therapeutics
  284. Precigen
  285. Precision BioSciences
  286. Preferred Cell Systems™
  287. Pregene ShenZhen Biotechnology
  288. Primorigen Biosciences (Acquired by Nucleus Biologics)
  289. ProMab Biotechnologies
  290. Promethera Biosciences
  291. PromoCell
  292. Provia Laboratories
  293. R&D Systems (Formerly known as Atlanta Biologicals)
  294. ReachBio Research Labs
  295. Regeneris Medical
  296. Regeneron
  297. Regeneus
  298. ReNeuron
  299. REPROCELL
  300. Rexgenero
  301. RHEACELL
  302. Riyadh Pharma
  303. RoosterBio
  304. Roslin Cell Therapies
  305. Rubius Therapeutics
  306. S.Biomedics
  307. Sangamo Therapeutics
  308. Sanvitra
  309. Saronic Biotechnology
  310. Sartorius
  311. ScienCell Research Laboratories
  312. Sclnow Biotechnology
  313. SCM Lifescience
  314. Seattle Genetics
  315. Sentien Biotechnologies
  316. Servier
  317. Shanghai Bioray Laboratory
  318. Shanghai GeneChem
  319. Shanghai Houchao Biotechnology
  320. Shanghai iCELL Biotechnology
  321. Shanghai Longyao Biotechnology
  322. Shanghai Unicar-Therapy Bio-medicine Technology
  323. Shenzhen BinDeBio
  324. Shenzhen Hornetcorn Biotechnology
  325. Shionogi
  326. Sigma-Aldrich (Acquired by Merck)
  327. Sinobioway Cell Therapy
  328. SMT Bio
  329. Sorrento Therapeutics
  330. SOTIO
  331. SQZ Biotech
  332. Stem Cell Arabia
  333. STEMCELL Technologies
  334. StemImmune
  335. Stemmatters 
  336. Sumitomo Dainippon Pharma
  337. Super-T Cell Cancer Company
  338. Surface Oncology
  339. Tactiva Therapeutics
  340. Taiwan Bio Therapeutics
  341. Takara Bio
  342. Takeda Pharmaceutical
  343. TapImmune 
  344. Targazyme
  345. TC BioPharm
  346. TCR2 Therapeutics
  347. Tella
  348. Tessa Therapeutics
  349. The Discovery Labs Center for Breakthrough Medicines
  350. Thermo Fisher Scientific
  351. ThermoGenesis
  352. Tianhe Stem Cell Biotechnologies
  353. TiGenix
  354. TILT Biotherapeutics
  355. Tmunity Therapeutics
  356. TNK Therapeutics
  357. TotipotentRX
  358. TRACT Therapeutics
  359. TransCure BioServices
  360. TreeFrog Therapeutics
  361. Trinova Biochem
  362. Triumvira Immunologics
  363. TVAX Biomedical
  364. Universal Cells
  365. U.S. Stem Cell
  366. Vaccinogen
  367. Vericel
  368. VetStem Biopharma
  369. ViroMed
  370. Viscofan BioEngineering
  371. Vitro Biopharma
  372. Waisman Biomanufacturing
  373. West Biotherapy
  374. Wissenschaftlicher Service Pharma (WiSP)
  375. Wuhan Sian Medical Technology
  376. WuXi AppTec (WuXi Advanced Therapies)
  377. Xcell Therapeutics
  378. Xcelthera
  379. XEME Biopharma
  380. Zelluna Immunotherapy 
  381. Zimmer Biomet
  382. Ziopharm Oncology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com